SynthesisOrthopaedic surgery2017
Selective Arterial Embolization for the Treatment of Sacral and Pelvic Giant Cell Tumor: A Systematic Review.
Synthesis in Orthopaedic surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Denosumab for Effective Tumor Size Reduction in Patients With Giant Cell Tumors of the Bone: A Systematic Review and Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Acetabular Giant Cell Tumor Presenting with Protrusio Acetabuli: A Rare Case Report.Journal of orthopaedic case reports · 2026Article
- Giant Cell Tumor of the Sacrum: A Narrative Review of Management Challenges and Modalities.Healthcare (Basel, Switzerland) · 2026Review
- Neoadjuvant chemotherapy, DEB-TACE, and 3D-printed prosthesis for primary pelvic pleomorphic undifferentiated sarcoma: a case report.Frontiers in oncology · 2025Article
- How Arterial Embolization Is Transforming Treatment of Oncologic and Degenerative Musculoskeletal Disease.Current oncology (Toronto, Ont.) · 2024Review
- Efficacy and safety of denosumab de‑escalation in giant cell tumor of bone.Oncology letters · 2024Article
- Giant cell tumor of bone and secondary osteoarthritis.Heliyon · 2024Review
- Current Concepts in the Treatment of Giant Cell Tumor of Bone: An Update.Current oncology (Toronto, Ont.) · 2024Review
- Partial sternectomy with reconstruction of a giant cell tumor of the sternum, a case report, Saudi, Arabia.Journal of cardiothoracic surgery · 2023Article
- Management of giant cell tumors of the distal radius.Journal of orthopaedics · 2023Article
- Denosumab combined with precision radiotherapy for recurrent giant cell tumor of the thoracic spine: a case report and literature review.Frontiers in neurology · 2023Article
- Multidisciplinary, articular surface-preserving treatment strategy for locally aggressive epithelioid hemangioma of the acetabulum employing serial bland transarterial embolization.Skeletal radiology · 2022Article
- Article
- Evaluating the Optimal Management of Inoperable Giant Cell Tumors of the Spine: A Systematic Review and Meta-Analysis.Cancers · 2022Review
- Intralesional nerve-sparing surgery versus non-surgical treatment for giant cell tumor of the sacrum.BMC musculoskeletal disorders · 2021Article
- Review
- Giant cell tumor of the sacrum.Proceedings (Baylor University. Medical Center) · 2020Article
- Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.Orthopaedic surgery · 2019Article
- Axial giant cell tumor - current standard of practice.Journal of clinical orthopaedics and traumaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell tumor of the bone (GCTB) is a locally aggressive tumor with a certain distant metastatic rate. For sacral GCT (SGCT) and pelvic GCT (PGCT), surgery has its limitations, especially for unresectable or recurrent tumors. Selective arterial embolization (SAE) is reported to be an option for treatment in several cases, but there are few systematic reviews on the effects of SAE on SGCT and/or PGCT. Medline and Embase databases were searched for eligible English articles. Inclusion and exclusion criteria were conducted before searching. All the clinical factors were measured by SPSS software, with P-values ≤0.05 considered statistically significant. A total of 9 articles were retrieved, including 44 patients receiving SAE ranging from 1 to 10 times. During the mean follow-up period of 85.8 months, the radiographic response rate was 81.8%, with a local control and overall survival rate of 75% and 81.8%, respectively. No bowel, bladder, or sexual dysfunction was observed. Three patients developed distant metastases and finally died. Patients with primary tumors tended to have better prognosis than those with recurrence (P = 0.039). The favorable outcomes of SAE suggest that it may be an alternative treatment for SGCT and PGCT patients for whom surgery is not appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.